Could Myovant Sciences LTD.HARES (NYSE:MYOV) Go Down After Its Newest Short Interest Report?

March 7, 2018 - By Adrian Mccoy

 Could Myovant Sciences LTD.HARES (NYSE:MYOV) Go Down After Its Newest Short Interest Report?

The stock of Myovant Sciences LTD.HARES (NYSE:MYOV) registered a decrease of 4.53% in short interest. MYOV’s total short interest was 430,300 shares in March as published by FINRA. Its down 4.53% from 450,700 shares, reported previously. With 26,800 shares average volume, it will take short sellers 16 days to cover their MYOV’s short positions. The short interest to Myovant Sciences LTD.HARES’s float is 2.94%.

The stock increased 2.72% or $0.416 during the last trading session, reaching $15.726. About 54,003 shares traded or 75.22% up from the average. Myovant Sciences Ltd. (NYSE:MYOV) has 0.00% since March 7, 2017 and is . It has underperformed by 16.70% the S&P500.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The company has market cap of $959.12 million. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

More notable recent Myovant Sciences Ltd. (NYSE:MYOV) news were published by: which released: “Myovant Sciences (MYOV) Presents at Baird’s 2017 Global Healthcare Conference …” on September 14, 2017, also with their article: “Roivant’s Myovant Sciences files for $173M IPO to fund its phase III-ready asset” published on October 04, 2016, published: “Myovant Sciences Ltd.” on November 21, 2016. More interesting news about Myovant Sciences Ltd. (NYSE:MYOV) were released by: and their article: “Myovant Sciences to Present at the 36th Annual JP Morgan Healthcare Conference” published on January 04, 2018 as well as‘s news article titled: “Myovant Sciences Provides Corporate Update and Reports Financial Results for …” with publication date: November 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: